Abstract Our recent studies demonstrated that the natural product nobiletin (NOB) served as a promising multidrug resistance (MDR) reversal agent and improved the effectiveness of cancer chemotherapy in vitro. However, low aqueous solubility and difficulty in total synthesis limited its application as a therapeutic agent. To tackle these challenges, NOB was synthesized in a high yield by a concise route of six steps and fourteen derivatives were synthesized with remarkable solubility and efficacy. All the compounds showed improved sensitivity to paclitaxel (PTX) in P-glycoprotein (P-gp) overexpressing MDR cancer cells. Among them, compound 29d exhibited water solubility 280-fold higher than NOB. A drug-resistance A549/T xenograft model showed that 29d, at a dose of 50 mg/kg co-administered with PTX (15 mg/kg), inhibited tumor growth more effective than NOB and remarkably increased PTX Abbreviations: Ac 2 O, acetic anhydride; AcOH, acetic acid; AcONa, sodium acetate; BF 3 $Et 2 O, boron trifluoride diethyl etherate; DCM, dichloromethane; DCE, dichloroethane; DMF, N,N-dimethylformamide; DMSO, dimethyl sulfoxide; DOX, doxorubicin; Et 3 N, triethylamine; Flutax-2, a fluorescent taxol derivative; MDR, multidrug resistance; NOB, nobiletin; NIS, N-iodosuccinimide; P-gp, P-glycoprotein; PI, propidium iodide; PTX, paclitaxel; QND, quinidine; Rho123, rhodamine 123; t-BuOK, potassium tert-butylate; TCA, trichloroacetic acid; THF, tetrahydrofuran; TLC, thin-layer chromatography; SRB, sulforhodamine B; Ver, verapamil. *Corresponding authors. Tel./fax: þ86 20 39943000. E-mail addresses: yxie@must.edu.mo (Ying Xie), luohb77@mail.sysu.edu.cn (Hai-Bin Luo). y These authors made equal contributions to this work. 
Introduction
As the second leading cause of death next to heart disease, cancer is a growing global threat with 18 million cases and 9.6 million deaths in 2018 around the world 1 . Chemotherapy is commonly used for treatment of many types of cancers, but multidrug resistance (MDR) often causes chemotherapy failure, leading to death of a majority of patients 2 . Overcoming drug resistance has far-reaching implications for cancer patients and society 3 . Cellular mechanisms of drug resistance have been classified into transportbased classical and nonclassical MDR phenotypes 3 . Overexpression of P-glycoprotein (P-gp, P-gp/ABCB1 encoded by the MDR1 gene), one of the ABC-family efflux transporters, is associated with poor prognosis in many types of cancers and is frequently observed in recurrent tumors in clinic 4 . In the past 20 years, three generations of MDR inhibitors have been developed to target efflux transporters, especially P-gp. Unfortunately, drawbacks of the targeted therapy occurred after treatment for long time 4 . Recently, studies on reversal of MDR by natural products and their synthesized analogues, such as secalonic acid D, epigallocatechin gallate derivative, WS-10, etc 5e7 . have received increasing attention. Among them, several fragments (Murcko, Murcko generic, RECAP and aromatic ring) are found to actively inhibit ABCB1 6 , serving as templates for designing new potent reversal agents to overcome MDR of cancers.
As a polymethoxy flavonoid isolated from tangerines, nobiletin (NOB, 3 0 ,4 0 ,5,6,7,8,-hexamethoxyflavone, Fig. 1 ) exhibits a good safety profile and a broad spectrum of pharmacological activities, such as anti-oxidative, anti-inflammatory 8 and anti-tumor effects 9 , especially high potency in cocktail therapy for drug-resistant cancers 10 . However, NOB exists as an aglycone, has poor water solubility (1e5 mg/mL) and low oral bioavailability (<1%), which limit its application as a therapeutic agent 11 . In addition to the traditional methods of separation and extraction, NOB could be prepared by total synthesis of over eleven steps 12 . Our recent studies demonstrated that NOB worked as an inhibitor of the MDR-efflux proteins by competing with chemotherapy drugs for the same binding site of P-gp, thus leading to improvement of the effectiveness of cancer chemotherapy in vitro 10 . NOB showed the MDR reversal ability to make the ovarian tumor cells of A2780/T, which resisted to paclitaxel (PTX), became >400 folds sensitive in comparison with its parent A2780 cells. Although there are lots of synthesized compounds or natural products demonstrated for their MDR reversal abilities, few of them have comparable reversal ability with NOB. In addition, our previous study revealed that NOB not only inhibited the P-gp function but also modulated the NRF2/PI3K/AKT pathways which are the important mechanisms of the MDR. These findings encourage further studies on producing NOB and its derivatives in a simpler and more effective synthetic way to find more potent and soluble products. Herein, to overcome the disadvantages and expand the scope of application, NOB was newly generated in high yield by a concise route of six steps and fourteen derivatives with remarkable solubility were synthesized. Further, we analyzed the efficacy of the compounds as MDR reversal agents in P-gp-overexpressing MDR cancer cells in vitro and in an A549/T xenograft model in vivo. We also investigated the underlying mechanism for the MDR reversal effects of NOB and its derivatives.
Results and discussion

Synthesis of the designed compounds
The target compounds were prepared by the synthetic routes reported in Schemes 1-3. First, commercially available 3,4,5-trimethoxyphenol (1) was selected as the starting material and reacted with acetic anhydride to afford the acetylation product 2, followed by Fries rearrangement to provide 3, which was then halogenated with N-iodosuccinimide to obtain Figure 1 Chemical structure of nobiletin (NOB). (5) was synthesized by the reaction of 4 with sodium methoxide in the presence of copper chloride 13 . Compounds 6a-6c were synthesized by acylation of 5 with the corresponding acyl chlorides 14 . The target compounds 7a-7c were obtained by cyclization of 6a-6c in the presence of triethylsilyl trifluoromethanesulfonate, respectively.
As outlined in Scheme 2, compounds 11 and 12 were obtained from 3 by treatment with bromine and nitric acid, respectively. Aryl esters 10, 14 and 15 were synthesized by acylation of 1-(2-hydroxyphenyl)ethan-1-ones with the corresponding acyl chlorides, which were treated with triethylsilyl trifluoromethanesulfonate to provide the corresponding flavones 13, 16 and 17. Subsequently, compound 17 was reduced by catalytic hydrogenation with Pd/C to afford 8-amino-2-(3,4-dimethoxyphenyl)-5,6,7-trimethoxy-4H-chromen-4-one (18) .
Furthermore, commercially available 2,3-dimethoxyphenol (19a) or 2,3,4-trimethoxyphenol (19b) were selected as the starting materials, and the same procedures as in Schemes 1 and 2 were used to obtain compounds 23a-23d (Scheme 3). The intermediate 21b was treated with iodomethane and K 2 CO 3 in the presence of N,N-dimethylformamide (DMF) to obtain 24, followed with nitric acid to afford compound 25. After 25 was reduced by catalytic hydrogenation with Pd/C to yield compound 26, it was treated with 3,4-dimethoxybenzoyl chloride to obtain 27. Finally, 27 was treated with t-BuOK in a solution of tetrahydrofuran (THF) to produce 2-(3,4-dimethoxyphenyl)-5,6,7,8-tetramethoxyquinolin-4(1H)-one (28) 15 . Compounds 29a-29d were synthesized by the reaction of 28 and corresponding alkyl halides in the presence of sodium hydride.
To avoid the interference of false positive compounds in our subsequent study, Pan Assay Interference Compounds (PAINS) screening of the designed compounds was carried out via an online program "PAINS Remover" (http://www.cbligand.org/PAINS/ ), and all of the compounds passed the filter and were retained.
NOB and its derivatives reverse ABCB1-mediated MDR
The IC 50 values of NOB and its derivatives against PTX-resistant HCT8/T cells (without adding 0.94 mmol/L PTX to the culture medium) were listed in Table 1 . These compounds showed antitumor effects against resistant human intestine and lung cancer cell lines, and their cytotoxicity are much lower than that of PTX (5.89 mmol/L in HCT8/T).
The long-term colony formation assays further ascertained the enhanced anti-proliferative effect of NOB and its derivatives on A549/T and HCT8/T cells, as shown in Fig. 2A and B. We noticed that NOB, 13 and 29d could inhibit MDR cancer cell colony formation in a dose-dependent manner. However, there is no difference in the inhibition of the colony formation among 13, 29d and NOB at their lowest effect dosage, indicating the similar reversal effects of NOB and its derivatives after long-time treatment.
As shown in Table 1 , NOB and its derivatives enhanced the anti-tumor effects of PTX by decreasing its IC 50 against the resistant HCT8/T cells. Specifically, the IC 50 values of PTX in the presence of NOB, 7c, 13 and 29d were reduced by 185-, 81-, 66-and 87-fold, respectively. However, NOB, 7c, 13 and 29d did not affect the IC 50 of PTX for the sensitive HCT8 cells (data not shown). In view of the relatively stronger cytotoxicity (38.46 mmol/L) of 7c than that of NOB, only 13, 29d and NOB were selected for further studies.
Structureeactivity relationships (SARs) of NOB and its derivatives
When a methoxy group was added at the C-5 position (7c) relative to 7b (NOB), the affinity decreased since there was insufficient space for accommodation of another methoxy group. The presence of 1,3-benzodioxole (7a) was unfavorable to affinity due to steric hindrance. For inhibitors 23a (one methoxy group), 23d (two methoxy groups), 13 (two methoxy groups) and 7b (three methoxy groups) with the same R 4 group, we found that more methoxy groups on the benzene ring A was propitious to better inhibitory potency, whereas the opposite phenomenon was observed on the R 4 position for 7b (two methoxy groups) and 7c (three methoxy groups). In addition, for inhibitors 13, 16 and 18, the bulky bromine atom of 16 or the NH 2 group of 18 at the R 1 group decreased the inhibitory affinity in comparison with the hydrogen atom of 13 16e18 .
On the basis of these results, we decided to retain the methoxy groups on the A and B rings and change the side chain at the X position. The dimethylaminoethyl sidechain of 29d formed hydrophobic and van der Waals interactions with the residues of P-gp, which significantly differs from NOB. Therefore, other modifications such as replacement of methylethyldimethylamine with 2-methoxyethyl (29c), H (28), Me (29a) or n-propyl (29b), were failed to improve their binding affinities. Thus, NOB, 29d and 13 were selected for subsequent study.
Moreover, the solubility data of NOB, 13 and 29d were measured as 5.58 AE 1.17, 3.67 AE 0.52 and 1.58 AE 0.13 mg/mL in sodium phosphate buffer (0.35 mol/L, pH Z 7.3) at 25 C, respectively, using the high-performance liquid chromatography (HPLC) approach. The presence of the dimethylaminoethyl sidechain of 29d possibly accounts for the notable improvement in the water solubility of 29d over NOB and 13 (280-fold higher), predicting that 29d possibly has better performance in vivo.
Anti-tumor effects in A549/T xenograft model
We next evaluated whether synthesized NOB and its derivatives could overcome PTX resistance in the A549/T xenograft model. Based on previous study, PTX was administered via intraperitoneal (i.p.) route at an effective dose (15 mg/kg) for normal tumor 19 . As expected, PTX alone exhibited no effect on treating MDR tumors, as shown by similar tumor progression between the PTX treated group and vehicle control group, indicating resistance (Fig. 3) . However, for the cocktail 29d and PTX administration, 29d at both 25 mg/kg and 50 mg/kg dosages significantly reduced the tumor volumes ( Fig. 3B-D) compared with PTX alone, indicating considerable therapeutic efficacy. Moreover, there was no apparent weight loss observed in all nude mice (Fig. 3A) , suggesting that the combination regimen did not bring additional toxicity. Notably, 29d (50 mg/kg) with PTX greatly reduced the volumes of tumors by 57% in the A549/T xenograft model, which is more effective than NOB at the same dosage (P < 0.05). Similarly, NOB derivative 13 also enhanced the therapeutic efficacy of PTX in the A549/T xenograft model (Fig. 4) . However, the tumor growth inhibition effect of 13 is similar to that of NOB.
Both 29d and 13 potentiate apoptosis induced by PTX
Consistent with the effects of NOB, 29d and 13 significantly potentiated the apoptosis induced by PTX, as shown in Fig. 5A and B, while PTX (5.89 mmol/L), 29d or 13 (9 mmol/L) alone did not induce cell apoptosis. Moreover, cell cycle progressions were evaluated by flow cytometry in asynchronously growing HCT8/T cells and sensitive HCT8 cells after treatment with PTX in the absence or presence of 29d or 13. When 0.94 mmol/L PTX was added to the culture medium of HCT8/T for maintaining resistance, 71.9% of cells in G1 phase and 17.1% of cells in G2 phase after incubation were observed, which is similar to the phase ratios in the vehicle group, as shown in Fig. 5C and D. However, PTX (0.94 mmol/L) treated with 29d or 13 (9 mmol/L) for 48 h resulted in significant G2M arrest (>80%) in HCT8/T cells. Therefore, 29d or 13 significantly enhanced the cell growth inhibition, apoptosis and G2M cell cycle arrest induced by 0.94 mmol/L PTX, although HCT8/T cells were remarkably resistant to 0.94 mmol/L PTX. 
29d and 13 inhibit the P-gp function
We also evaluated the modulating effects of synthesized NOB and its derivatives on P-gp by evaluating the accumulation of Pgp substrates, including doxorubicin (DOX) and flutax-2 (a fluorescent PTX derivative), using fluorescence microscopy and flow cytometry analysis. Enhanced intracellular accumulations of DOX or flutax-2 by NOB and its derivatives were confirmed by flow cytometry analysis, as shown in Fig. 6A and C. Moreover, stronger fluorescence signals of DOX and flutax-2 were observed by adding NOB, 29d, 13 and quinidine (QND, positive control), as shown in Fig. 6B and D. The effects of 29d on the intracellular accumulation were stronger than those of 13 and NOB.
LC-MS/MS was used to detect the contents of PTX, 29d and NOB in the tumors growing in the A549T xenograft model after treatment. Compared with the PTX alone group, NOB enhanced the content of PTX in tumors by 2.93-fold, while 29d enhanced by 4.82-fold, which was approximately 1.65-fold that of NOB (Fig. 7A) . Moreover, the concentration of 29d in tumor tissues was significantly increased by 1.72-fold in the PTXþ29d (50 mg/kg) group compared with the 29d (50 mg/kg) group (Fig. 7B ), indicating that 29d and PTX were competing for binding on P-gp. All of these results suggested that synthesized NOB and its derivatives could inhibit P-gp function in MDR cancer cells which led to increased intracellular chemotherapeutic agents to kill the MDR Total synthesis and discovery of potent MDR reversal agentscancer, and 29d exhibited a stronger inhibition effect on the function of P-gp than 13 and NOB.
Putative binding pattern of 29d to the pocket of P-gp
To show the putative binding pattern, 29d was docked by the Surflex-dock module embedded in Tripos Sybyl X 2.0 (St. Louis, USA) to the crystal structure of P-gp in complex with QZ59-RRR (PDB ID: 4M2S). The selected binding pose of 29d fitted the binding pocket well, with Surflex docking score (Total-Score) of 6.2274. In this binding modes ( Fig. 8 and Supporting Information Section 1), several kinds of specific interactions between 29d and P-gp were observed. Inhibitor 29d formed two H-bonds with Tyr306 and Gln721, respectively. Strong p-p and p-s interactions were also observed for 29d with residues Phe979, Phe339, Phe724 and Phe728. In addition to van der Waals interactions and hydrophobic interactions with residues of Phe299, Gln986, Ile302 and Ser725, the dimethylaminoethyl sidechain of 29d formed extra interactions with Leu335 and Phe331, which significantly differed from NOB 10 . Subsequently, molecular dynamics (MD) simulations were applied for a more precise prediction of binding patterns using AMBER 14. As a result, the predicted binding free energies of the P-gp/29d and P-gp/NOB complexes were À43.99 AE 3.12 and À39.47 AE 2.62 kcal/mol, respectively. From the MD simulation results, apparent hydrophobic interactions with residues Phe299, Phe724, Phe728, Phe979 and Leu336 in P-gp were observed by 29d and NOB. In addition, 29d and NOB formed hydrogen bonds with Gln721 and Tyr306, respectively. Nevertheless, dimethylaminoethyl chain of 29d formed extra van der Waal interactions with Phe339 and Ile302, which might account for its more negative binding free energy compared with NOB.
NOB and its derivatives overcome MDR via AKT/ERK/ NRF2 pathway
Multiple targets are characteristics of natural products and ultimately offer clinical benefits in comparison with the three generations of MDR inhibitors 20 . To explore the underlying mechanisms for functions of NOB and its derivatives, we evaluated the signaling pathways ( Fig. 9 ) of NRF2/PI3K/AKT and ERK, which had been shown to be closely associated with resistance to chemotherapy drugs 16 . Interestingly, we found that Nrf2, phosphorylated AKT and ERK were significantly reduced in HCT8/T cells after administration of NOB, 29d or 13, while the expression of total AKT and ERK remained the same (Fig. 9) . These results indicated that the MDR reversal effects of 29d and 13 to chemotherapy agents were produced by the inhibition of Nrf2/PI3K/AKT pathways, the same as NOB.
Change of sensitivity of the MDR cancer cells to drugs could be due to reduction of ABCB1 expression, competitive inhibition of the ABCB1 transporter, or both. Therefore, we evaluated the effects of synthesized NOB, 29d and 13 on the expression of Total synthesis and discovery of potent MDR reversal agentsABCB1. Interestingly, none of them at the reversal concentrations alter the protein level of ABCB1 in HCT8/T cells (Fig. 9 ). In addition, NOB and its derivatives did not affect the expression of BCRP and MDR1 in A549/T cells (Fig. 10 ) which are two major efflux transporters related to the PTX resistance. Thus, synthesized NOB and its derivatives likely inhibited ABCB1 transporter function but did not affect the expression of ABCB1.
Several metabolites of NOB including 3
0 -didemethylnobiletin and 5,3 0 ,4 0 -tridemethylnobiletin have been identified as the major metabolites from the urine of mouse by the optimized HPLC method [21] [22] . Anti-inflammatory effects of 4 0 -demethylnobiletin on TPA-induced mice ear inflammation have been shown through inhibition of PI3K/AKT/ERK phosphorylation 22 . Therefore, the metabolites of NOB derivatives possibly have inhibitory activity on P-gp function via the NRF2/PI3K/AKT pathways. 
Conclusions
In short, NOB was produced with a high yield by total synthesis of six steps and fourteen derivatives were synthesized to discover potent compounds with remarkable solubility and efficacy as MDR reversal agents. Among them, 29d showed 280-fold higher water solubility than NOB and 13. As a result, 29d significantly increased PTX concentration in the tumor in vivo and showed a stronger tumor growth inhibition than NOB and 13 after coadministered with PTX. Moreover, our studies demonstrated that the activated NRF2/PI3K/AKT pathways in MDR cancer cells were remarkably inhibited by the conjunction of 29d and PTX. C NMR spectra were recorded at room temperature (rt) on a Bruker AVANCE III 400 instrument (Germany) with tetramethylsilane (TMS) as an internal standard. The following abbreviations are used: s (singlet), br s (broad singlet), d (doublet), dd (doublet of doublets), t (triplet), q (quartet) and m (multiplet). Coupling constants were reported in Hz. Highresolution mass spectra (HRMS) were recorded on SHIMADZU LCMS-IT-TOF (Kyoto, Japan). The purities of compounds were determined by reverse-phase HPLC analysis, confirming purity to exceed 95%. HPLC instrument: SHIMADZU LC-20AT (column: Hypersil BDS C18, 5.0 mm, 150 mm Â 4.6 mm (Elite); detector: SPD-20A UV/VIS detector, UV detection at 254 nm; elution, MeOH in water (80%, v/v); T Z 25 C; flow rate Z 1.0 mL/min; Kyoto, Japan).
3,4,5-Trimethoxyphenyl acetate (2)
A mixture of 1 (9.2 g, 50 mmol) and sodium acetate (8.2 g, 100 mmol) in acetic anhydride (47 mL, 500 mmol) was heated at 110 C for 2 h. TLC analysis (petroleum ethe/ethyl acetate Z 7:3) showed completion of the reaction. Then the reaction mixture was concentrated under reduced pressure, diluted with water and extracted with ethyl acetate thrice. The organic phase was washed Figure 9 Effects of the combination treatment of PTX with 29d, 13 and NOB (N) on expressions of P-gp, AKT, ERK and NRF2 in HCT8/T cells. Cells were treated with 9 mmol/L 29d, 13 and N for 48 h. Equal amounts of total lysate were used for Western blot. Combination treatment of PTX with 29d, 13 or NOB did not influence P-gp expression, but reduced the level of NRF2 as well as the phosphorylation of AKT/ERK. The experiments were repeated three times. The data were shown as mean AE SD. * P < 0.05 and ** P < 0.01. Figure 10 The expression of efflux transporters P-gp, MRP2 and BCRP in A549/T and HCT8/T cells, and the effects of 29d and NOB (N) on their expression by comparing with sensitive A549 or HCT8 cells (red frame). Cells were treated with 9 mmol/L 29d or N for 48 h. Equal amounts of total lysate were loaded and detected by Western blot. with brine, dried over anhydrous sodium sulfate. The organic layer was concentrated to afford the product 2 (11.2 g) as a white solid, which was used directly in the next step without further purification. Yield: 91%. 1 
1-(6-Hydroxy-2, 3, 4-trimethoxyphenyl) ethanone (3)
Boron trifluoride etherate (ca. 48% BF 3 , 250 mL) was added to a solution of 2 (11.2 g, 50 mmol) in glacial acetic acid (37.5 mL). The reaction mixture was stirred at 70 C for 2 h. TLC analysis (petroleum ether/ethyl acetate Z 7:3) showed completion of reaction. Then the reaction mixture was quenched with water and extracted with ethyl acetate. The organic phase was washed with brine, dried over anhydrous sodium sulfate, and purified by silica gel column chromatography (petroleum ether/ethyl acetate Z 10:1) to afford product 3 (10.2 g) as a yellow oil. Yield: 91%. 1 
1-(2-Hydroxy-3-iodo-4,5,6-trimethoxyphenyl) ethanone (4)
Adding NIS (1.4 g, 6.0 mmol) and p-toluenesulfonic acid monohydrate (950 mg, 5.0 mmol) to a stirred solution of 3 (1.1 g, 5.0 mmol) in CH 3 CN (50 mL). The mixture was stirred at rt for 2 h until the start material disappeared as monitored by TLC. After evaporated under vacuum, the reaction mixture was extracted with ethyl acetate. The organic phase was washed with saturated aqueous sodium thiosulfate and brine, and dried over anhydrous sodium sulfate. The solvent was evaporated to afford product 4 as a yellow-green solid, which was used directly in the next step without further purification. Yield: 73%. 
General procedure for synthesis of compounds 6aÀ6c
To a solution of 5 (128 mg, 0.5 mmol) in dichloromethane (2.5 mL) was added triethylamine (208 mL, 1.5 mmol) and acyl chlorides (0.65 mmol) at 0 C. The mixture was stirred at rt for 2 h. Then the reaction mixture was quenched with water and extracted with ethyl acetate. The organic phase was washed with brine, dried over anhydrous sodium sulfate, and purified by silica gel column chromatography (petroleum ether/ethyl acetate Z 5:1) to afford the product as white solids. , 1H), 6.07 (s, 2H), 3.98 (s, 3H), 3.93 (s, 3H) , 3.90 (s, 3H), 3.81 (s, 3H), 2.47 (s, 3H). 
. 1 . 5 . 2 . 2 -A c e t y l -3 , , 5 , 6 -t e t r a m e t h o x y p h e n y l 3 , -dimethoxybenzoate (6b
General procedure for synthesis of compounds 7a-7c
To a solution of 6 (0.4 mmol) in dichloroethane (2.4 mL) was added triethylamine (166 mL, 1.2 mmol) and trimethylsilyl trifluoromethanesulfonate (434 mL, 2.4 mmol). The mixture was stirred at 95 C for 2 h, then quenched with CH 3 OH, and extracted with ethyl acetate. The organic phase was washed with brine, dried over anhydrous sodium sulfate, and purified by silica gel column chromatography (petroleum ether/ethyl acetate Z 2:1) to afford the product. 97 (s, 6H), 3.91 (s, 3H), 3.90 (s, 3H), 2.51 (s, 3H) .
4.1.8. 1-(3-Bromo-2-hydroxy-4,5,6-trimethoxyphenyl) ethanone (11) Sodium acetate (1.77 g, 21.6 mmol) was added to a solution of 3 (4.436 g, 19.6 mmol) in glacial acetic acid (15 mL). Then Br 2 in glacial acetic acid (1.5 mL, 29.4 mmol) was added dropwise to the reaction mixture at 0 C. The mixture was stirred at rt for 12 h and poured into ice water (150 mL). The solid was filtered and washed with water to yield product 11 as a yellow solid, which was used directly in the next step without further purification. Yield: 81%. To a solution of 10 (1.17 g, 3.0 mmol) in dichloroethane (18 mL) was added triethylamine (1.2 mL, 9.0 mmol) and trimethylsilyl trifluoromethanesulfonate (3.3 mL, 18 mmol). The mixture was then stirred at 95 C for 2 h, quenched with CH 3 OH, and extracted with ethyl acetate. The organic phase was washed with brine, dried over anhydrous sodium sulfate, and purified by silica gel column chromatography (petroleum ether/ethyl acetate Z 2:1) to afford product 13 (905 mg) as a brown solid. Yield: 81%. Purity: 99%. 1 96 (s, 3H), 3.95 (s, 3H), 3.93 (s, 3H), 2.52 (s, 3H) .
To a solution of 14 (1.2 g, 2.6 mmol) in dichloroethane (15 mL) was added triethylamine (1.0 mL, 7.5 mmol) and trimethylsilyl trifluoromethanesulfonate (2.7 mL, 15 mmol). The mixture was stirred at 95 C for 2 h, then quenched with CH 3 OH and extracted with ethyl acetate. The organic phase was washed with brine, dried over anhydrous sodium sulfate, and purified by silica gel column chromatography (petroleum ether/ethyl acetate Z 1:1) to afford product 16 (900 mg) as a white solid. Yield: 79%. Purity: 99%. 
2-(3,4-Dimethoxyphenyl)-5,6,7-trimethoxy-8-nitro-4H-chromen-4-one (17)
To a solution of 15 (1.9 g, 4.3 mmol) in dichloroethane (26 mL) was added triethylamine (1.7 mL, 13 mmol) and trimethylsilyl trifluoromethanesulfonate (4.6 mL, 256 mmol). The mixture was stirred at 95 C for 2 h, then quenched with CH 3 OH and extracted with ethyl acetate. The organic phase was washed with brine, dried over anhydrous sodium sulfate, and purified by silica gel column chromatography (petroleum ether/ethyl acetate Z 1:1) to afford product 17 (1.5 g) as a brown solid. Yield: 84%. A mixture of 19b (5.5 g, 30 mmol) and sodium acetate (4.9 g, 60 mmol) in acetic anhydride (28 mL, 300 mmol) was heated at 110 C for 2 h. TLC analysis (petroleum ether/ethyl acetate Z 9:1) showed completion of the reaction. Then the reaction mixture was concentrated under reduced pressure, diluted with water and extracted with ethyl acetate thrice. The organic phase was washed with brine, dried over anhydrous sodium sulfate. The organic layer was concentrated to afford product 20b (6.4 g) as a brown yellow oil, which was used directly in the next step without further purification. Yield: 94%. 
1-(2-Hydroxy-3,4-dimethoxyphenyl) ethan-1-one (21a)
A mixture of 19a (1.5 g, 10 mmol) and sodium acetate (1.6 g, 20 mmol) in acetic anhydride (9.4 mL, 100 mmol) was heated at 110 C for 2 h. TLC analysis (petroleum ether/ethyl acetate Z 9:1) showed completion of the reaction. Then the reaction mixture was concentrated under reduced pressure, diluted with water and extracted with ethyl acetate thrice. The organic phase was washed with brine and dried over anhydrous sodium sulfate. The organic layer was concentrated to afford product 20a (1.9 g) as a red brown oil, which was used directly in the next step without further purification. Then boron trifluoride etherate (ca. 48% BF 3, 48.5 mL) was added dropwise to a solution of compound 20a (1.9 g, 9.7 mmol) in glacial acetic acid (7.5 mL). The reaction mixture was stirred at 70 C for 2 h. TLC analysis (petroleum ether/ethyl acetate Z 7:3) showed completion of reaction. Then the reaction mixture was quenched with water and extracted with ethyl acetate. The organic phase was washed with brine, dried over anhydrous sodium sulfate, and purified by silica gel column chromatography (petroleum ether/ethyl acetate Z 10:1) to afford product 21a (1.8 g) as a brown solid. Yield: 95%. 
General procedure for synthesis of compounds 22a-22d
To a solution of compound 21aÀ21d (196 mg, 1.0 mmol) in dichloromethane (5 mL) was added triethylamine (418 mL, 3.0 mmol) and acyl chloride (1.5 mmol) at 0 C. The mixture was stirred at rt for 2 h, then quenched with water and extracted with ethyl acetate. The organic phase was washed with brine, dried over anhydrous sodium sulfate, and purified by silica gel column chromatography (petroleum ether/ethyl acetate Z 5:1) to afford the products 22a-22d as white solids. 
General procedure for synthesis of compounds 23aÀ23d
To a solution of 22 (0.8 mmol) in dichloroethane (4.8 mL) was added triethylamine (332 mL, 2.4 mmol) and trimethylsilyl trifluoromethanesulfonate (868 mL, 4.8 mmol). The mixture was stirred at 95 C for 2 h, then quenched with CH 3 OH and extracted with ethyl acetate. The organic phase was washed with brine, dried over anhydrous sodium sulfate, and purified by silica gel column chromatography (petroleum ether/ethyl acetate Z 2:1) to afford the products 23aÀ23d. To a solution of 25 (1.9 g, 6.7 mmol) in tetrahydrofuran (134 mL) was added Pd/C catalyst (285 mg, 15%) under an atmosphere of H 2 at 40 C for 15 h. After cooling to rt, the mixture was filtered with diatomite and washed with ethyl acetate. The organic layer was evaporated under vacuum to afford a residue, which was purified by silica gel column chromatography (petroleum ether/ ethyl acetate Z 2:1) to yield product 26 (1.6 g) as a brown yellow oil. Yield: 95%. To a solution of 26 (570 mg, 2.2 mmol) in dichloromethane (11 mL) was added triethylamine (915 mL, 6.6 mmol) and 3,4-dimethoxybenzoyl chloride (883 mg, 4.4 mmol) at 0 C. The mixture was stirred at rt for 2 h, then quenched with water and extracted with ethyl acetate. The organic phase was washed with brine, dried over anhydrous sodium sulfate, and purified by silica gel column chromatography (petroleum ether/ethyl acetate Z 5:1) to afford product 27 (738 mg) as a white solid. Yield: 80%. 
General procedure for synthesis of compounds 29bÀ29d
To a solution of 28 (0.2 mmol) in anhydrous DMF (2.0 mL) was added sodium hydride (48 mg, 2.0 mmol). The mixture was stirred at 90 C for 30 min and chloralkanes (0.6 mmol) was added. Then the reaction mixture was further stirred at 90 C for 2 h. After cooled to rt, the solution was poured into water and acidified by the addition of 2.0 mol/L aqueous HCl. The resulting solution was extracted with portion of ethyl acetate. The combined organic extracts were washed with brine, dried over anhydrous sodium sulfate, and concentrated to give crude, which was purified by
